Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

May 1, 2027

Conditions

Overall Response Rate

Interventions

DRUG

Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2

Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2, repeat use on 21st day if the serous effusion not controlled

DRUG

cisplatin 40mg/m2 intracavity injection

Trial Locations (1)

RECRUITING

Qingdao Central Hospital, Qingdao

All Listed Sponsors

lead

Qingdao Central Hospital

OTHER

NCT07090525 - Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions | Biotech Hunter | Biotech Hunter